Merck & Co., Inc. stock (US58933Y1055): Earnings, pipeline and US market role

Merck & Co., Inc. has reported its latest quarterly results, highlighting continued growth in its oncology and vaccine franchises while providing updates on its late?stage pipeline and capital?allocation priorities. The figures and commentary come at a time when the company remains a key player in the US pharmaceutical market and a major component of many US?based healthcare portfolios.

For the most recent quarter, Merck posted revenue of about 17.8 billion USD, up roughly 10% year?over?year, driven by strong demand for its flagship cancer drug Keytruda and solid performance in vaccines and hospital medicines, according to Merck investor relations as of May 8, 2026. Adjusted earnings per share rose to about 2.20 USD, reflecting both volume growth and disciplined cost management. The company also reiterated its full?year guidance, signaling confidence in its core franchises despite ongoing pricing and reimbursement pressures in the US and Europe.

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

Merck & Co., Inc.: core business model

Merck & Co., Inc. operates as a global research?driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines and vaccines. Its business model centers on high?margin, patent?protected products in areas such as oncology, infectious diseases, diabetes and cardiovascular health, with a strong emphasis on innovation and lifecycle management.

The company generates the bulk of its revenue from branded prescription drugs and vaccines sold to hospitals, pharmacies, governments and insurers. In the United States, Merck benefits from a large insured patient base and established relationships with payers, while internationally it leverages partnerships and local affiliates to expand access in emerging markets. The firm also invests heavily in research and development, typically allocating more than 20% of annual sales to R&D, which underpins its long?term growth strategy.

Main revenue and product drivers for Merck & Co., Inc.

Merck’s oncology portfolio, led by the PD?1 inhibitor Keytruda, remains the single largest revenue driver. Keytruda is approved for multiple cancer types, including lung, melanoma and head and neck cancers, and continues to gain new indications through clinical trials and regulatory submissions. In the latest quarter, Keytruda sales grew in the mid?teens percentage range year?over?year, supported by expanded use in earlier?line settings and combination therapies.

Vaccines represent another major pillar, with products such as Gardasil (HPV), MMR II and pneumococcal vaccines contributing steady, recurring revenue. The company has also advanced its pipeline in infectious diseases, including investigational vaccines for respiratory syncytial virus (RSV) and other respiratory pathogens, which could broaden its footprint in preventive care. Hospital and specialty medicines, including diabetes and cardiovascular agents, round out the portfolio and provide diversification beyond oncology.

Why Merck & Co., Inc. matters for US investors

For US investors, Merck & Co., Inc. is a core healthcare holding due to its scale, diversified product mix and exposure to long?term demographic trends such as aging populations and rising cancer incidence. The company’s strong presence in the US market, where it generates a significant share of global sales, makes it particularly relevant for portfolios focused on domestic healthcare exposure.

Merck also offers a relatively stable dividend profile, with a history of regular payouts and modest increases, which can appeal to income?oriented investors. At the same time, its pipeline?driven growth model introduces optionality around new drug approvals and label expansions, creating potential upside if late?stage candidates succeed in clinical trials and gain regulatory clearance.

Conclusion

Merck & Co., Inc. continues to balance near?term earnings growth with long?term innovation, supported by a leading oncology franchise, a broad vaccine portfolio and a disciplined capital?allocation approach. The latest quarterly results and pipeline updates underscore the company’s position as a major player in the global pharmaceutical industry and a key name for US?based healthcare investors.

However, investors should remain mindful of risks such as patent expirations, pricing pressures, regulatory scrutiny and clinical trial outcomes, all of which can influence the stock’s performance over time. As with any equity investment, a diversified approach and careful consideration of individual risk tolerance are important when evaluating Merck & Co., Inc. as part of a broader portfolio.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.